Wells Fargo & Company Raises Crescent Capital BDC (NASDAQ:CCAP) Price Target to $19.00

Crescent Capital BDC (NASDAQ:CCAP) had its target price raised by stock analysts at Wells Fargo & Company from $18.00 to $19.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential downside of 2.79% from the stock’s previous close.

Separately, Keefe, Bruyette & Woods upped their price objective on Crescent Capital BDC from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, November 25th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Crescent Capital BDC Stock Performance

CCAP stock traded up $0.11 on Wednesday, hitting $19.55. The company had a trading volume of 10,761 shares, compared to its average volume of 78,899. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.14. Crescent Capital BDC has a 12-month low of $15.91 and a 12-month high of $20.03. The stock has a market cap of $724.34 million, a price-to-earnings ratio of 7.64 and a beta of 0.81. The stock’s 50-day simple moving average is $19.38 and its 200 day simple moving average is $18.76.

Crescent Capital BDC (NASDAQ:CCAP) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.07. Crescent Capital BDC had a return on equity of 12.20% and a net margin of 47.06%. The business had revenue of $51.63 million during the quarter, compared to the consensus estimate of $48.76 million. During the same period in the previous year, the company posted $0.59 EPS. As a group, equities research analysts expect that Crescent Capital BDC will post 2.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Crescent Capital BDC

Institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. grew its stake in Crescent Capital BDC by 11.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 105,343 shares of the company’s stock valued at $2,025,000 after acquiring an additional 11,161 shares in the last quarter. Redhawk Wealth Advisors Inc. purchased a new position in shares of Crescent Capital BDC during the fourth quarter valued at about $659,000. Confluence Investment Management LLC increased its holdings in shares of Crescent Capital BDC by 0.9% in the fourth quarter. Confluence Investment Management LLC now owns 73,839 shares of the company’s stock worth $1,419,000 after purchasing an additional 633 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Crescent Capital BDC by 35.2% in the third quarter. Franklin Resources Inc. now owns 256,279 shares of the company’s stock worth $4,726,000 after purchasing an additional 66,713 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new stake in shares of Crescent Capital BDC in the third quarter worth about $4,878,000. Institutional investors own 49.46% of the company’s stock.

Crescent Capital BDC Company Profile

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.